For the association between mutation abundance and 6-month survival (Fig. 3), patients with high KRAS mutation abundance in tumor significantly more often had an OS < 6 months (P = 0.046), and those with high KRAS mutation abundance in ctDNA significantly more frequently had an OS < 6 months (P < 0.001) and a PFS < 6 months (P = 0.027). This evidence concerns the gene KRAS and neoplasm.